Diatrizoate in computed cranial tomography: a quantitative study.
Plasma diatrizoate concentrations during computed cranial tomography were measured by UV spectrophotometry in 14 patients. A loading dose of 0.82 mg diatrizoate/kg followed by a stead infusion of 0.01 mg/kg was required to attain and maintain plasma concentrations of approximately 400 mg/100 ml. Lowering the beam energy resulted in a substantial increase in the EMI numbers of diatrizoate and significant improvement in the delineation of contrast containing lesions. A contrast index estimating the volume of pixel containing diatrizoate was calculated for five diagnosed lesions and this factor appears to be related to vascularity and extravasation.
D000230:Adenocarcinoma / Q000000981:diagnostic imaging; D000328:Adult; D001927:Brain Diseases / Q000000981:diagnostic imaging*; D001932:Brain Neoplasms / Q000000981:diagnostic imaging; D003287:Contrast Media; D003973:Diatrizoate / Q000031:analogs & derivatives*; D003974:Diatrizoate Meglumine; D005260:Female; D006801:Humans; D002538:Intracranial Arteriovenous Malformations / Q000000981:diagnostic imaging; D002542:Intracranial Embolism and Thrombosis / Q000000981:diagnostic imaging; D008297:Male; D008579:Meningioma / Q000000981:diagnostic imaging; D008875:Middle Aged; D009362:Neoplasm Metastasis; D011859:Radiography
D003287:Contrast Media; D003973:Diatrizoate; D003974:Diatrizoate Meglumine